Cluster or IBN Description
Flanders.health is the regional business network for new healthcare propositions at the crossroads of life-science and digital technology. Home to those that see their business change because of exponential technology growth, home to providers of solutions, home to integrators that can pull things together. Flanders.health engages in ‘collaborative business development’. It complements each individual company’s efforts to acquire new business, by looking at the overall potential of technology across a value chain, exploring areas beyond the perspective of a single company, and engaging in discussions with stakeholders that are best reached in a collective manner.
Flanders.health has collaboration at its core; founded by three established cluster organizations (FlandersBio, DSP Valley and MedTech Flanders), it fosters a cross-over ecosystem, and while enabling and welcoming bilateral business, its main contribution lies in the establishment of larger collaborations. As such, flanders.health works towards a thriving ecosystem. The potting soil for any company’s success.
For more information: see here
08:30: departure from FMCCA, Antwerp to Arenberg science park, Leuven
Brief introduction of flanders.health and Health House on the bus
09:45-11:15: visit Health House (Leuven)
11:15-12:15: interactive networking lunch
12:15-12:45: drive or walk (1.8km, weather permitting) to health sciences campus Gasthuisberg
12:45-14:15: visit to ParTICLe; a proton therapy centre
14:15-15:00: travel to Mechelen
15:00-16:30: visit to Cochlear Technology Centre Europe (CTCE)
16:30-17:15: return to FMCCA, Antwerp
Case of flanders.health
The business network of flanders.health started towards the end of 2018 to find in 6 months’ time no less than 80 business propositions needing attention. With two calls, in the area of personalized medicine and in disease prevention, the installed manpower was already oversubscribed.
In part, this success is due to the bootstrapping effect of a foundation by 3 well established cluster organizations. Quite probably though, there is more to it.
Both life sciences and digital technologies ride on exponential growth curves, and the improvements they can bring to healthcare are enormous. Better outcomes with continued affordability are key drivers. But many innovations work against the set ways of the healthcare system, run into privacy concerns or ethical considerations, or need to be wrapped into unobtrusiveness to gain patient acceptance. Tons of technology are needed to make new possibilities really work. That, along with policy changes and multidisciplinary approaches. A complex cocktail that no single company alone can work out.
Flanders.health helps its member companies overcome this complexity.Bolstering the expertise of its founding organizations, being multidisciplinary by construction, it propels those business cases that have the best chance of making a significant impact.
Members of flanders.health / Companies
How will technology have an impact on the future of our health and care? Health House takes you on an innovative and interactive trip to the future of healthcare. A 3D movie theatre shows the wonders of genetics and DNA in an almost tangible fashion. A Kinect room shows how 3D printing can help treat the human body, a digital anatomy table allows virtual surgery and real life scan analysis, and a VR room lets you dive into the human brain to find out all there is to know about epilepsy and ways to combat it.
House showcases these technologies in a very innovative and interactive way.
The university hospitals UZ Leuven and Saint-Luc, along with the universities of Louvain-la-Neuve and Leuven invest in a brand-new treatment and research centre for proton therapy, the first in Belgium. This will be done in collaboration with various other university and regional hospitals, as well as research institutes. The ‘Particle Therapy Interuniversity Centre Leuven’ (ParTICLe) is also supported by the Flemish Government.
About 40 to 50% of all cancer patients receive radiotherapy at some point during their treatment, be it as monotherapy or in combination with chemotherapy and/or targeted drugs.
Despite the great progress in conventional photon (X-ray) therapy over the past years, it remains difficult to spare healthy tissue surrounding the tumor. Proton therapy has the potential to significantly reduce the radiation damage thereby improving patient outcomes.
In the new proton therapy centre also research will be performed in order to further develop proton therapy. The research includes both clinical and fundamental research and will be performed in cooperation with the industry.
Cochlear is the global leader in implantable hearing solutions with products including cochlear implants, bone conduction implants and acoustic implants. The company invests more than $160 million each year in R&D and has provided more than 550,000 implant solutions to date. Cochlear’s Technology Centre in Mechelen is focused on advanced innovation in new technologies, products and processes, and is a prime example of how collaboration in an ecosystem spurs success.
2 Bridge CVBA - Aardex - Academic Labs - Achilles - ADX Neurosciences - Aesculape - Akcelis - Anacura - Anima (incl Aneurotech) - Antleron - Asylia Diagnostics - Atlas Neuro Engineering - Bewell Innovations - Biogazelle - Bioncise - CellSine - Checkmed - Comate - Confluence Consulting bvba - COVARTIM - Datastories - Elmedix - Ergotrix - Flanders Vaccine - Flen Health - Fujirebio - Helpilepsi - HICT - Howest - Icometrix - Inovigate - Janssen Pharmaceutica - KBC Verzekeringen - KUL - LiCalab - Maastricht Universiteit - Meddition - Modis - moveUp - MSD - Novosanis - Ontoforce - Origanius - Palindromo Consulting - Pilot Biologix - Provincie Vlaams-Brabant - Qualix - Quantum Management & Consulting - reMynd - Rode kruis Vlaanderen - Salvus Health - Select Projects - Sensinxs NV - Siemens Digital Industries - Simabs - U Antwerpen - U Hasselt, BioMed - U Hasselt, CenStat - U Hasselt, LCRC ( in collaboration with ZOL) - Unitron - Verhaert - VITO - Voxdale - VUB - ZOL
No special requirements.